Itamar Medical Gains Most in 4 Months on Chinese Approval

Itamar Medical Ltd. (ITMR) rose the most in almost four months after the maker of medical diagnostic equipment said two of its products were approved for distribution in China.

The shares gained 5.6 percent, the biggest increase since Dec. 7, to 2.08 shekels at the 4:30 p.m. close in Tel Aviv.

WatchPAT, a device for diagnosing sleep apnea, and the company’s non-invasive cardiovascular device EndoPAT can now be sold in the Asian country.

To contact the reporter on this story: Ronit Goodman in Tel Aviv at rgoodman9@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.